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ABSTRACT
Objective To assess the clinical effectiveness of weekly
delivery of low dose, high frequency therapeutic
ultrasound in conjunction with standard care for hard to
heal venous leg ulcers.
Design Multicentre, pragmatic, two arm randomised
controlled trial.
Setting Community and district nurse led services,
community leg ulcer clinics, and hospital outpatient leg
ulcer clinics in 12 urban and rural settings (11 in the
United Kingdom and one in the Republic of Ireland).
Participants 337 patients with at least one venous leg
ulcer of >6 months’ duration or >5 cm
2 area and an ankle
brachial pressure index of ≥0.8.
Interventions Weekly administration of low dose, high
frequency ultrasound therapy (0.5 W/cm
2, 1 MHz, pulsed
pattern of 1:4) for up to 12 weeks plus standard care
compared with standard care alone.
Main outcome measures Primary outcome was time to
healing of the largest eligible leg ulcer. Secondary
outcomes were proportion of patients healed by
12months,percentageandabsolutechangeinulcersize,
proportion of time participants were ulcer-free, health
related quality of life, and adverse events.
Results The two groups showed no significant difference
in the time to healing of the reference leg ulcer (log rank
test, P=0.61). After adjustment for baseline ulcer area,
baseline ulcer duration, use of compression bandaging,
and study centre, there was still no evidence of a
difference in time to healing (hazard ratio 0.99 (95%
confidence interval 0.70 to 1.40), P=0.97). The median
timetohealingofthereferencelegulcerwasinestimable.
Therewasnosignificantdifferencebetweengroupsinthe
proportion of participants with all ulcers healed by
12 months (72/168 in ultrasound group v 78/169 in
standard care group, P=0.39 for Fisher’s exact test) nor in
the change in ulcer size at four weeks by treatment group
(model estimate 0.05 (95% CI –0.09 to 0.19)). There was
no difference in time to completehealing of all ulcers (log
rank test, P=0.61), with median time to healing of
328 days (95% CI 235 to inestimable) with standard care
and 365 days (224 days to inestimable) with ultrasound.
There was no evidence of a difference in rates of
recurrence of healed ulcers (17/31 with ultrasound v 14/
31 with standard care, P=0.68 for Fisher’s exact test).
Therewasnodifferencebetweenthetwogroupsinhealth
related quality of life, both for the physical component
score (model estimate 0.69 (–1.79 to 3.08)) and the
mentalcomponentscore(modelestimate –0.93(–3.30to
1.44)),butthereweresignificantlymoreadverseeventsin
the ultrasound group (model estimate 0.30 (0.01 to
0.60)). There was a significant relation between time to
ulcer healing and baseline ulcer area (hazard ratio 0.64
(0.55 to 0.75)) and baseline ulcer duration (hazard ratio
0.59 (0.50 to 0.71)), with larger and older ulcers taking
longer to heal. In addition, those centres with high
recruitment rates had the highest healing rates.
Conclusions Low dose, high frequency ultrasound
administered weekly for 12 weeks during dressing
changes in addition to standard care did not increase
ulcer healing rates, affect quality of life, or reduce ulcer
recurrence.
Trial registration ISRCTN21175670 and National
Research Register N0484162339
INTRODUCTION
Leg ulceration is a chronic, recurring condition that
affects 1.5–1.8% of adults in industrialised countries
1
(with venous leg ulcers representing up to 84% of leg
ulcers
2) and has a considerable impact on health and
quality of life.
23High compression bandaging is effec-
tive treatment,
4 healing most new venous leg ulcers
(<6 months’ duration) within a year.
5 The priority is
now to increase healingin ulcers with poorer prognos-
tic profiles (bigger and older ulcers).
Ultrasound therapy is a standard treatment option
for soft tissue injuries in physiotherapy clinics, and it
is used in some centres for the management of chronic
wounds
6andisrecommendedinsomeclinicalpractice
guidelines.
7-9 It is thought that using low intensity
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2) can be used to stimulate nor-
mal physiological responses to injury to aid repair.
10
Other ultrasound regimens, delivered in a water bath,
have been used with the primary aim of debriding
wounds.
11
A systematic review of trials of ultrasound therapy
for treating venous leg ulcers suggested that it
improved healing.
12 Meta-analysis of the four trials
that reported data on complete ulcer healing at 8–
12 weeks produced a relative risk for healing of 1.44
(95% confidence interval 1.01 to 2.05). However, the
trials identified were methodologically weak, hetero-
geneous, prone to bias, and varied widely in applica-
tion regimens.
To investigate this further, we conducted a rando-
misedcontrolledtrialtocomparetheeffectofstandard
ulcer care alone with standard care plus ultrasound
treatment. We measured time to healing of the refer-
ence ulcer, health related quality of life, proportion of
participants with ulcers healed at 12 months, percen-
tage and absolute change in ulcer size, adverse events,
and cost of treatments. The economic evaluation is
reported separately.
13
METHODS
Ultrasound treatment
The dose at which ultrasound is delivered is related to
its frequency (hertz), power (watts), pulsed or continu-
ouscycle,andthedurationofthetreatment,whichcan
produce many possible combinations.
14 Therapeutic
ultrasound has a frequency of 0.75–3.0 megahertz
(MHz), and most machines used to deliver it are set at
a frequency (that is, cycles per second) of either 1 or 3
MHz.
15 The total amount of energy in an ultrasound
beam is expressed in watts (W) indicating its power.
15
At the time our study was designed, most evidence
was available for ultrasound treatment at a frequency
of 1 MHz and dose of 0.5 W/cm² (including the one
study in the systematic review with only moderate
risk of bias). Previous trials had evaluated ultrasound
administered weekly, two or three times a week, or
with declining frequency of administration. Adminis-
tering ultrasound requires bandage removal, and
hence our choice of treatment regimen balanced the
costs of these visits against the potential reduction in
healing time (if ultrasound were effective). We there-
forechosealowdose,highfrequencyultrasoundtreat-
ment (1 MHz at 0.5 W/cm
2) with a pulse pattern set at
1:4 and the duration of each treatment being deter-
mined by ulcer area. Treatment was delivered once
weekly for up to 12 weeks.
Participants and setting
This was a pragmatic, multicentre, two arm, rando-
mised controlled, open trial with equal randomisation
carried out in 11 centres in the United Kingdom and
one in the Republic of Ireland. Participants were
recruited between March 2006 and December 2008
(end of extended recruitment period) from services
led by community and district nurses, community leg
ulcerclinics,andhospitaloutpatientlegulcerclinicsin
urban and rural settings. Centres were recruited
through staff from our known community of leg ulcer
servicesandclinics.Allvenouslegulcerpatientsonthe
treatment lists within these centres were assessed for
trial inclusion by completion of a screening form by
either their usual nursing team or a study research
nurse. Systematic methods were used to approach
and potentially recruit participants.
Nurse training
Before the trial started, participating nurses attended a
trainingdayintheircentrewhichcoveredtherationale
for the study, patient eligibility, recruitment and con-
sent procedures, data collection, adverse event report-
ing, and the ultrasound application technique
according to the manufacturer’s instructions and clin-
ical expertise. Competency in ultrasound application
was assessed at the end of the training. Trained nurses
werepermittedtotrainotherlocalnursestoallowtreat-
ments to be maintained during staff absences. Contin-
ual support was available from the trial coordinator.
Treatment fidelity checks were not undertaken.
This model of training reflected the likely invest-
mentintrainingthatwouldbeavailableintheNational
Health Service if the intervention proved successful
and was rolled out to community nursing services
and hospital outpatients. To maintain the pragmatic
nature of the trial, we did not impose a regimen of
observation of practice greater than there would be in
standard care.
Patient eligibility
Eligible participants had venous leg ulcers of
>6 months’ duration or >5 cm
2 in size, or both. A par-
ticipant was considered to have a venous leg ulcer if
there was no other evident cause and clinical assess-
mentsuggesteditwasvenous(moist,shallow,irregular
shape, venous eczema, ankle oedema, lipodermato-
sclerosis, not confined to the foot) and participants
had had an ankle brachial pressure index of ≥0.8
within the past three months. If participants had more
than one ulcer, the largest eligible ulcer was defined as
the reference ulcer, which would be followed through-
out the study and, if allocated, receive the ultrasound
therapy.
We originally planned to recruit only those able to
toleratehighcompressionbandages.However,clinical
collaborators argued that those who can tolerate only
reduced compression therapy represent a particular
challenge to treat and might benefit in particular from
any effect of therapeutic ultrasound. We therefore
removed the inclusion criterion of “willing and able
to wear four-layer high compression bandaging.”
Participants were excluded if their leg ulcer was due
to other causes, they were of childbearing age, were
allergic to ultrasound contact gel, had poorly con-
trolled diabetes (HbA1c >10% measured within the
past three months), or had any of the known contra-
indications to ultrasound (including ankle or knee
prosthesis or metal in the lower leg, suspected throm-
bophlebitis, active cellulitis, and suspected or
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ginal protocol also stated the study would not recruit
people with rheumatoid arthritis, peripheral arterial
disease, or diabetes. However, after discussions with
clinical collaborators, the first two criteria were
removed as unnecessary, and the last was replaced by
“poorly controlled diabetes.”
Ethical approval was gained for all changes. Partici-
pants gave written, informed consent.
Patient randomisation
Those patients deemed potentially eligible according
to the screening form were seen by one of the trained
nurses,who explained the study, confirmed eligibility,
and obtained written consent. Consenting patients
were randomised to receive ultrasound plus standard
care or standard care alone. Randomisation was per-
formed by the nurses telephoning an independent,
secure, remote, randomisation service (York Trials
Unit) thereby concealingtreatment allocation. Rando-
misation was carried out by permuted block design
with varying block sizes of four and six. Because of
the nature of the intervention, it was not possible to
blind either the patient or the nurse to the treatment.
Intervention
The ultrasound therapy was applied with a SoLo
Therasonic 355 machine (EMS Physio, Wantage,
UK). Before use, all the trial machines were tested by
the National Physical Laboratory (Teddington, UK).
Measurements were made of total acoustic power and
effective radiating area, and these were within the
tolerance of ±20% specified by IEC 60601-2-5 and
IEC 61689. The machines were serviced regularly
throughout the trial.
Treatment was given weekly at the patients’ regular
dressing changes. After removal of all dressings and
bandaging,the woundwascleaned asusual. Theultra-
sound transducer head was sterilised with alcohol
wipes. Ultrasound was then applied to the skin sur-
rounding the reference ulcer, using a water based con-
tact gel recommended by the manufacturer, for 5–
10 minutes by moving the transducer head in a slow,
controlled manner around the edges of the ulcer in
overlapping circles to cover the skin evenly. Ulcers of
area <5 cm
2 received ultrasound for five minutes,
those of ≥10 cm
2 received 10 minutes’ ultrasound.
For ulcers between 5 cm
2 and 10 cm
2, treatment time
inminutesequalledtheulcerareaincm²(ulcerof6cm
2
area=6minutes’treatment).Aftertreatment,alltraces
of the contact gel were removed and the transducer
head was cleaned with alcohol wipes. After the
12 weeks of ultrasound, participants returned to stan-
dard care alone.
Treatment before study enrolment was not formally
recorded, but standard care comprised low adherent
dressings and four-layer bandaging that was high com-
pression, reduced compression, or no compression,
depending on the patient’st o l e r a n c e ,r e p l a c e da te a c h
weeklyvisit.Changestothisregimen,asdeemedappro-
priate by the treating clinician, were recorded. Since
standard care also reflected treatment as usual accord-
ing to local practice, it could vary between centres.
Outcome measurement
The primary outcome was time to complete healing of
the reference ulcer. Ulcer healing was defined as full
epithelial cover without scab. Digital photographs of
the reference ulcer were taken every four weeks, at
point of healing, and seven days after healing by the
treating nurse. Photographs were assessed by two
remote,independentassessorswhowereblindtotreat-
mentallocationtodeterminethedateofhealingandto
protectthestudyagainstassessmentbiases.Anydiscre-
pancies were referred to a third assessor. The primary
outcome was calculated using the date of healing as
decided by the blinded assessors. However, if no
photographs were available for a patient, then the
date of healing decided by the treating nurse was
taken as the healed date.
Secondaryoutcomes(notallreportedherebutinour
economic evaluation
13) included the proportion of
patients with ulcers healed at three, six, and
12 months, proportion of time ulcer-free, change in
ulcer area, recurrence rates, health related quality of
life, and adverse events. Ulcer area was calculated
every four weeks (before ultrasound delivery) by the
nurse tracing the perimeter on an acetate grid with a
fine-nibbed pen, following a standard method that is
accurate and reliable.
16 As leg ulcer care is most com-
monlydeliveredinthehome,itwasnotfeasibletohave
Assessed for eligibility (n=1488)
Randomised (n=337) (299 screening forms returned)
Screening forms returned with no exclusion boxes ticked (n=378)
Allocated to standard care
 only (n=169):
    Received standard care
      (n=169)
    Full withdrawal (n=17)
    Withdrawal from nurse
      collected data only (n=3)
Allocated to ultrasound +
  standard care (n=168):
    Received ultrasound at
      least once (n=159)
    Full withdrawal (n=14)
    Withdrawal from nurse
      collected data only (n=0)
Included in primary
analysis (n=169)
Included in primary
analysis (n=168)
Excluded (n=1110):
  Patient was in VenUS III trial previously (n=5)
  Patient has ≥1 contraindications to ultrasound (n=121)
  Patient is woman of childbearing potential (n=5)
  Patient is in another leg ulcer trial (n=25)
  Patient is allergic to ultrasound or gel (n=1)
  Ankle brachial pressure index <0.8 (n=232)
Patients not randomised (n=79):
  Being considered for VenUS II trial (n=51)
  Healed (n=5)
  Eczema (n=3)
  Lives outside area (n=2)
  Plastic surgeon referral (n=1)
  Unknown reason (n=17)
Fig 1 | Flow of participants through trial
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changestotracetheulcer.Tracingdataweremeasured
using a computer package (Mouseyes).
17
Patients’ perceptions of health outcome were
assessed with the short form 12 (SF-12), which is sensi-
tive to changes in venous ulcer healing status.
18 Ques-
tionnaireswereadministeredbypostatthree,six,nine,
and 12 months.
Serious adverse events were defined as death, life
threatening risk, hospitalisation, persistent or substan-
tialdisabilityorincapacity,andothermedicallyimpor-
tant conditions (such as being newly diagnosed with
diabetes). Other adverse events were classed as non-
serious. Reporting nurses indicated whether, in their
opinion, the event was related to the trial treatment.
A list of possible treatment related adverse events was
established a priori, based on the literature and the
VenUS I and II trials
519 (including pressure damage,
infection, new ulcer, and ulcer deterioration).
Statistical analysis
All analyses weredoneinSAS version9.1 and STATA
version10onanintentiontotreatbasiswithatwosided
5% significance level. Scoring of the SF-12 question-
naire’s health related quality of life was done with the
QualityMetric Health Outcomes Scoring Software 2.
Allowing for 10% attrition, we estimated that a total
of336participantswouldprovide90%powertodetect
a reduction in the median time to healing from
22 weeks to 15 weeks. The control healing time was
based on trial data for large or chronic ulcers: 13–
37% of people with chronic and large ulcers heal at
24 weeks with high compression.
20 Our target popula-
tion included people with chronic or large ulcers, and
from previous trials,
5 we estimated that about 50% of
ulcers in the standard care group would heal within
22 weeks. As ultrasound increases treatment time and
is not currently used by community nurses, we anti-
cipated that clinicians would require a moderate effect
size for them to adopt this technology; hence a reduc-
tion in healing time from 22 to 15 weeks was deemed
clinically meaningful. The minimum clinically impor-
tant effect size is related to the ease of delivery of the
intervention, its acceptability, and costs, both in initia-
tion and ongoing delivery.
Our primary analysis compared time to complete
healing of the reference ulcer between the two rando-
mised groups using a Cox regression model.
21 Shared
centrefrailty(random)effectswereassumedtofollowa
γ distribution, and STATA was used to fit a Cox survi-
val regression model. The analysis adjusted for centre
as a random effect, ulcer area (from baseline tracing),
ulcer duration, and whether the patient was treated
with high compression bandaging (as fixed effects).
These factors were chosen because they had been
prognostic in other leg ulcer studies.
519 The distribu-
tion of baseline ulcer area and baseline ulcer duration
were highly skewed, so we used the logarithm of base-
line ulcer area and ulcer duration in the subsequent
analysis. Patients who withdrew from the study or
whose reference ulcer had not healed by trial conclu-
sion were treated as censored. If centres recruited five
or fewer patients we repeated the analysis with no
adjustment for centre as a sensitivity analysis.
The assumption of proportional hazards was
checked by using log-log plots, by including inter-
action terms in the model (for each term with time),
and by looking at plots of Schoenfeld residuals.
Kaplan-Meier survival curves describing time to heal-
ing were produced for the two groups and the median
time to healing with 95% confidence interval.
Cohen’s κ measure of inter-rater agreement was
used to assess agreement between the two assessors of
thephotographsforhealing.Thiswasrepeatedtolook
at agreement between the final decision from the
photographassessmentandthenurses’dateofhealing.
Ulcerareaatweek4wascomparedbetweentreatment
groups using analysis of covariance to adjust for base-
line ulcer area, centre, ulcer duration, and use of com-
pression bandaging.
We analysed the scores for the physical and mental
health components of the SF-12 questionnaire using a
multi-level regression model. The outcomes at each
timepointwereusedinasinglemodel,withtimepoints
nestedwithinparticipantstoaccountforwithin-patient
correlation in scores. The model was used to estimate
the difference between treatments over the whole
12 month follow-up. The outcome modelled was the
score at each follow-up assessment, and the covariates
includedin the modelwere centre,baselineulcerarea,
ulcer duration, use of compression, and time (indica-
torsfor0, 3,6,9 and12 months).Weassessedwhether
the pattern in quality of life scores over time was
Table 1 |Baseline characteristics of 337 patients with venous leg ulcers who were
randomised to standard care alone or to ultrasound plus standard care. Values are numbers
(percentages) unless stated otherwise
Characteristic
Standard care
(n=169)
Ultrasound
(n=168)
Overall
(n=337)
M e n 7 3( 4 3 ) 6 4( 3 8 ) 1 3 7( 4 1 )
Women 96 (57) 104 (62) 200 (59)
Age (years):
Mean (SD) 69.92 (14.21) 68.91 (14.80) 69.44 (14.50)
Median (range) 71.91 (20–98) 71.64 (26–95) 71.85 (20–98)
Reference ulcer area (cm
2):
Mean (SD) 27.18 (41.96) 27.95 (44.47) 27.56 (43.17)
Median (range) 12.0 (1.0–283.5) 12.0 (1.0–268.0) 12.0 (1.0–283.5)
Reference ulcer duration (months):
≤6 5 6( 3 3 ) 4 2( 2 5 ) 9 8( 2 9 )
>6 113 (67) 126 (75) 239 (71)
Oldest ulcer duration (months):
Mean (SD) 33.58 (56.38) 33.93 (66.91) 33.75 (61.76)
Median (range) 11 (0–36) 12 (0–516) 12 (0–516)
High compression bandaging used:
Yes 148 (88) 145 (86) 293 (87)
No 21 (12) 23 (14) 44 (13)
ABPI of reference limb:
Mean (SD) 1.08 (0.21) 1.06 (0.19) 1.07 (0.20)
Median (range) 1.10 (0.08–1.64) 1.06 (0–1.69) 1.08 (0–1.69)
ABPI=ankle brachial pressure index.
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interaction term between treatment and time in the
model.
We assessed the assumption of normally distributed
data and, if necessary, used log transformations or
other analysis methods.
We used a negative binomial model
22 adjusting for
the same covariates as the primary analyses, to com-
pare the average number of adverse events experi-
enced by each patient in the two treatment groups.
Separate analyses were performed for serious and
non-serious adverse events.
RESULTS
BetweenJanuary2006andDecember2008,1488peo-
plewithlegulcerswerescreenedacross12centres,and
337 (22.6%) were randomised: 168 to ultrasound plus
standardcareand169tostandardcare.Figure1shows
the flow of participants through the trial, and table 1
summarises their baseline characteristics.
Table 2 gives details of the compression bandaging
provided, for both groups, and the ultrasound treat-
ment for the intervention group. Participants in the
ultrasound group had a median of 11 ultrasound treat-
ments during the 12 week ultrasound period (mean
10.25).
Primary outcomes
Wefoundnoevidenceofadifferenceintimetohealing
between the two treatment groups with either the log
ranktest(logrankteststatistic0.25,P=0.61)orWilcox-
on’s rank sum test (Wilcoxon test statistic 0.33,
P=0.56). Figure 2 shows the Kaplan-Meier survival
curve for time to healing of reference ulcers in both
groups.
FortheCoxmodel,theproportionalhazardassump-
tion was tested and was not violated, either separately
for each covariate (ultrasound v standard care
(P=0.7230), log(area) (P=0.1467), log(duration)
(P=0.2938), high compression (P=0.2030)) or globally
(P=0.3548)). Hence, all hazard ratios were assumed
constant during the follow-up period. From the Cox
proportionalhazardsmodel,afteradjustmentforbase-
lineulcerarea,baselineulcerduration,useofcompres-
sion bandaging, and study centre (as a random effect),
there was still no evidence of a difference in time to
healing between the two treatment groups (hazard
ratio 0.99 (95% confidence interval 0.70 to 1.40),
P=0.97). There was, however, significant heterogene-
ity in the healing rates among centres (P=0.0001) not
explainedbythecovariatesincludedinthemodel.We
found that centres recruiting more participants were
associated with higher healing rates than centres
recruiting fewer participants.
The median time to complete healing of all ulcers in
thestandardcaregroupwas328days(95%confidence
interval 235 days to inestimable) and in the ultrasound
groupwas365days(224daystoinestimable).Figure3
shows the Kaplan-Meier survival curve for time to
complete healing of all ulcers in both groups.
Table 2 |Treatment details for 337 patients with venous leg ulcers who were randomised to
standard care alone or to ultrasound plus standard care
Standard care (n=169) Ultrasound (n=168)
Total No (%) of bandages applied: 6473 (100) 8013 (100)
Four layer high compression 2241 (35) 2151 (27)
Three layer high compression 1543 (24) 2325 (29)
Three layer reduced compression 668 (10) 1063 (13)
Two layer high compression 857 (13) 921 (11)
Short stretch compression 805 (12) 848 (11)
Low compression 139 (2) 250 (3)
No compression 220 (3) 455 (6)
No of ultrasound applications per person:
Mean (SD) — 10.25 (2.96)
Median (range) — 11 (1–15)
No (%) of participants with missing values — 9 (5)
Proportion of consultations where ultrasound applied:
Mean (SD) — 0.77 (0.24)
Median (range) — 0.86 (0.14–1.00)
No (%) of participants with missing values — 9 (5)
Total duration of ultrasound applications per person
(minutes):
Mean (SD) — 73.94 (31.69)
Median (range) — 69.0 (9.0–130.0)
No (%) of participants with missing values — 9 (5)
Time (days)
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Fig 2 | Kaplan-Meier survival curve for time to healing of
reference ulcers among 337 patients with venous leg ulcers
randomised to standard care alone or to ultrasound plus
standard care
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Fig 3 | Kaplan-Meier survival curve for time to complete
healing of all ulcers among 337 patients with venous leg
ulcers randomised to standard care alone or to ultrasound
plus standard care
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There was no significant difference between the two
groups in the proportionofparticipantswith allulcers
healed (according to the nurse forms) by 12 months
(72/168 in ultrasound group v 78/169 in standard
caregroup,P=0.3854forFisher’sexacttest).Forcom-
parison with other studies, there was no difference in
the proportions of reference ulcers healed (according
toblindedassessmentofphotographs)atthreemonths
(28/168 v 30/169 standard care, P=0.8854) or at six
months (48/168 v 52/169, P=0.7208).
WeusedCohen’sκmeasuretoassesstheagreement
between the two blinded assessors of the ulcer photo-
graphs and whether the assessors agreed with the
unblinded nurse as to whether the reference ulcer had
healed. The photograph assessors’ measure of agree-
ment was estimated as 0.84 (95% confidence interval
0.78to0.90),andagreementbetweentheassessorsand
the nurse was 0.76 (0.69 to 0.83).
Of the 133 participants with photographically con-
firmed healing of their reference ulcer, 124 were suc-
cessfully contacted later to ascertain whether their
ulcer had recurred. The remaining participants were
not contacted for various reasons (including invalid
or changed telephone number, telephone not
answered, and patient moved). Overall, the reference
ulcer had recurred in 31 (25%) of the 124 participants
(14(45%)fromthestandardcaregroup,17(55%)from
the ultrasound group). There was no significant differ-
ence in the recurrence rates between the two groups
(P=0.68 for Fisher’s exact test).
Weanalysedulcerareaafterfourweeksoftreatment
to determine whether ultrasound affected rate of heal-
ing (baseline ulcer area was included in the model as a
covariate). There was a non-significant ultrasound
treatment effect (model estimate 0.05 (95% CI –0.09
to 0.19), P=0.50) and a non-significant ulcer compres-
sion effect (model estimate 0.02 (–0.19 to 0.24),
P=0.84).Baselineulcerareaanddurationbothhadsig-
nificant effects on the initial change in ulcer area
(model estimates 0.77 (0.72 to 0.84) and 0.13 (0.07 to
0.19) respectively, both P=0.0001): smaller and newer
ulcers reduced in area more quickly. There was no
evidence of any difference between centres (model
estimate 0.01, P=0.15).
Atbaseline,themeanphysicalcomponentsummary
score of the SF-12 questionnaire was 36.55 (SD 11.32)
fortheultrasoundgroupand35.33(11.47)forthestan-
dardcaregroup(comparedwithascoreof43.93(9.29)
for people aged 65–74 years in the general US popula-
tion),andthemeanmentalcomponentsummaryscore
was 46.72 (11.52) for the ultrasound group and 47.11
(11.29) for the standard care group (compared with
51.57 (8.36) for the general US population). Response
ratesfortheSF-12questionnaireswere89%,84%,81%,
and 86% at three, six, nine, and 12 months respec-
tively.Figures4and5showlittlechangeinthephysical
and mental component scores over time: hence there
was a constant linear trend of both scores against time.
Therewasnoevidenceofadifferencebetweenthetwo
treatment groups in the mean physical component
summary scores (model estimate 0.69 (–1.79 to 3.08),
P=0.58) or the mean mental component summary
scores (model estimate –0.93 (–3.30 to 1.44), P=0.44).
There were 88 serious adverse events in 64 partici-
pants:29participants(45%)inthestandardcaregroup
and 35 (55%) in the ultrasound group. There were 445
non-serious adverse events in 153 participants: 67
(44%) were in the standard care group and 86 (56%)
in the ultrasound group. When we set the model
response as the number of serious adverse events per
patient throughout follow-up, we found no significant
difference in adverse events due to treatment received
(model estimate 0.23 (–0.34 to 0.79), P=0.39) or base-
line use of compression bandaging (model estimate
–0.16 (–0.98 to 0.65), P=0.66). There was weak evi-
dence that larger baseline ulcer area and longer base-
line ulcer duration were associated with more serious
adverse events (model estimates 0.19 (–0.03 to 0.40),
P=0.08, and 0.22 (–0.02 to0.45), P=0.06, respectively).
The number of non-serious adverse events was sig-
nificantly associated with the treatment received, with
more events in the ultrasound group than the standard
caregroup(modelestimate0.35(0.02to0.67),P=0.04)
but was not related to baseline ulcer area (model esti-
mate 0.05 (–0.08 to 0.17), P=0.42), baseline ulcer dura-
tion (model estimate 0.08 (–0.06 to 0.22), P=0.24), and
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(–0.46 to 0.47), P=0.99).
DISCUSSION
We found no evidence that therapeutic low dose, high
hertz frequency ultrasound delivered once a week
improves the healing of venous leg ulcers. We did
observe a significant centre effect, such that rates of
ulcer healing differed significantly between treatment
centres.Acentre’shealingratewasproportionaltothe
number of participants. There was no evidence of
ultrasound having an effect on healing when analysed
by centre. As there was little change in the SF-12 ques-
tionnaire’sphysicalcomponentsummaryscoreduring
thetrialineithergroupandnoevidenceofasignificant
change in the mental component summary score over
time, ultrasound showed no impact on health related
quality of life.
Bandaging use was recorded6473 times for the peo-
ple treated with standard care and 8013 times for the
peopletreatedwithultrasound.Werethelevelofcom-
pressionofbandagestodiffersignificantlybetweenthe
two groups, then this might introduce a performance
bias. The proportion of visits at which high compres-
sion systems (four layer, three layer, or two layer) was
used was 67% (5397/8013) for ultrasound and 72%
(4641/6473)forstandardcare.Theproportionofvisits
at which no compression was used was 3.4% (220/
6473) in standard care and 5.7% (455/8013) in the
ultrasound group. The modest differences in the level
of compression used (fewer in the standard care group
had no compression) were not significant, and hence
performance bias is unlikely to account for the lack of
evidence of benefit with ultrasound.
Although there were more adverse events in the
ultrasound group than the standard care group, as
ultrasound is not currently used in practice, it is possi-
ble that nurses were more likely to attribute adverse
events (such as ulcer deterioration) to a treatment
with which they are relatively unfamiliar. The overall
adverseeventrate(thenumberofpeoplereportingany
adverseevent)wassimilartothatintheVenUSItrial,
5
which reported an event rate of about 40%.
Strengths and limitations of study
The strengths of this study include the large sample
size, wide inclusion criteria, blinded allocation, use of
best available standard treatment, blinded outcome
assessment, low loss to follow-up, collection of quality
of life and effectiveness data, and long duration of fol-
low-up.Limitationsincluded the modestresponserate
from patients at 12 months in respect of the quality of
life questionnaires.
Inaddition,thereisthepossibilityofrandomerrorin
the evaluation of the ulcer area when traced using the
computer software.
17 However, the ulcers were mea-
sured every four weeks for the purpose of dose adjust-
ment, and, although this was done by the unblinded
nurse, there is no reason for systematic errors (bias)
being introduced as the primary outcome measure
was time to complete healing as assessed by a blinded
assessor. Any doubts regarding the potential errors in
ulcer measurements confirm the importance of the
more robust outcome measure of time to healing with
the addition of a blinded outcome assessment to con-
firm this.
Rationale for this study
Reviewsofearliertrialevidenceforthe effectsofultra-
sound in wound healing generally
23 and leg ulcers
specifically
12 identified the potential benefit of ultra-
sound therapy for venous ulcer healing. However, a
definitive study was needed since these trials were
small, had methodological weaknesses, and had
incomplete reporting and were at high risk of bias.
Furthermore, the clinical contexts in which the trials
had taken place (such as before the widespread intro-
duction of high compression therapy) meant that their
relevance to today’s leg ulcer management was uncer-
tain. Since completion of our study, an updated sys-
tematic review has been published with eight trials
included, six using high frequency ultrasound and
two using low frequency ultrasound.
24
Wenowknowfromprognosticstudiesandtrialsthat
high compression therapy heals some 80% of venous
ulcers within 12 months and that ulcers smaller than
5c m
2 and of less than six months’ duration are likely
to heal quickly.
20 In designing this trial, we therefore
felt that adding an adjuvant ultrasound therapy to the
treatmentofsmallornewulcerswasunwarranted.The
sample size of a trial to find a benefit of adding ultra-
sound to the treatment of most venous ulcers would
have to be very large given the high healing rate. We
therefore recruited people with hard to heal ulcers—
those for whom clinicians might consider additional
interventions beyond standard care. On the whole,
participants’ ulcers were large (12 cm
2) and chronic
(1 yearduration), and thoserecruited were representa-
tive of the venous ulcer population in terms of age and
sex.
1
There are two explanations for our findings: firstly,
that there is a treatment effect but our trial failed to
detect it (due to chance or to methodological pro-
blems), or, secondly, ultrasound therapy at the dose
and frequency used does not accelerate healing of
hard to heal venous ulcers. We minimised the play of
chance by having a large sample size. We minimised
detection bias by using confirmed healing date by
photographic assessment. The possibility that ultra-
sound machines did not deliver the prescribed dose
was reduced by having them serviced and calibrated
regularly, and we recorded all treatments given to
ascertain if there was evidence of performance bias
(such as extra treatments in the standard care group),
which there was not.
Our decision to use low dose, high frequency ultra-
sound therapy (0.5 W/cm
2, 1 MHz, pulsed pattern of
1:4) administered weekly was based on earlier evi-
dence (the largest trial) and the need to balance the
delivery of leg ulcer care in an efficient manner, with
weekly visits to renew dressings and bandages, against
the desire to deliver ultrasound more frequently. We
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this was a pragmatic approach to evaluating the addi-
tion of a novel therapy that took account of the extra
treatment time required by the nurse. We felt that ask-
ing nurses to apply ultrasound for the whole trial per-
iodwouldhaveresultedindisillusionmentifnursesfelt
that there was no discernable benefit, as this would
increase the workload significantly: this would have
hampered recruitment. The lack of any treatment
effect, as seen in the Kaplan-Meier curves, seems con-
sistentwiththerebeingnoeffectonhealingratewithin
the first 12 weeks. Given the widely accepted use of
compression therapy, replaced usually once or twice
a week, it would be impractical to deliver ultrasound
other than at the regular bandage renewal; hence our
rationale for weekly ultrasound to integrate with cur-
rent practice.
Implications of results
Herewereportthelargesttrialundertakenoftherapeu-
tic ultrasound for wound healing.
23-25 This trial is also
much larger than any trial of ultrasound for fractures
included in a recent systematic review
26 and was con-
ducted and reported in accordance with international
guidelines for research excellence.
2728
We designed this trial in 2003, when there were
seven trials summarised in a systematic review,
12 two
of which were not randomised. If we now add the
VenUS III data into that meta-analysis (by taking our
numbers of ulcers healed at 12 weeks), we find that,
although more ulcers healed with ultrasound than
with sham ultrasound or standard care, the difference
was not statistically significant (P=0.095). Further-
more,VenUSIIIistheonlytrialtomeetallthevalidity
criteria of adequate randomisation, full allocation con-
cealment, blinded outcome assessment, and analysis
based on intention to treat, so we would argue that
the VenUS III result is the most valid. The conclusion
we therefore draw from all the evidence is that thera-
peutic ultrasound does not confer any benefit on the
healing of hard to heal venous leg ulcers (that is, >5
cm
2 in area or >6 months old, or both).
However, we evaluated only one ultrasound regi-
men, and so our results cannot be extrapolated to
other regimens, such as those delivering ultrasound
via a water bath to debride wounds. We identified a
large variation in healing rates according to trial cen-
tres, with those centres recruiting more participants to
thetrialhavinghigherhealingratesoverall.Thiscentre
effect may be a manifestation of a relation between the
volume of throughput and the quality of care. This
finding is worthy of further exploration. Other
research questions include the evaluation of the effec-
tiveness of this and alternative ultrasound regimens,
say through value of information approaches.
Implications for clinicians are that there is no evi-
dence to support the addition of ultrasound therapy
to treatments for people with hard to heal leg ulcers.
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